Indivior Pharmaceuticals (INDV) executive compensation, 2026 proxy

Joe Ciaffoni, Chief Executive Officer, was paid $18.5M in 2025. The CEO-to-median-employee pay ratio was 146:1, on median employee pay of $129,375.

Filed
March 27, 2026
Annual meeting
May 13, 2026
Pay year
2025
Named executives
7
CEO total pay
$18.5M2025
CEO to median employee
146:1median $129,375
CEO pay in equity
83%$15.3M in awards
CEO Base Salary
$1,050,000Annualized base salary for CEO
Total Net Revenue
$1.24B4% increase year-over-year
SUBLOCADE Revenue
$856M13% increase year-over-year
Adjusted EBITDA
$428M20% increase year-over-year
GAAP Net Income
$210MSignificant increase from 2024

How Ciaffoni was paid

$18.5M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary4%Stock awards83%Non-equity incentive11%All other compensation2%

Named executive officers

ExecutiveTotal
Joe CiaffoniChief Executive Officer$18,501,214
Mark CrossleyFormer Chief Executive Officer$3,185,591
Ryan PreblickChief Financial Officer$3,592,393
Christian HeidbrederChief Scientific Officer$4,182,548
Pat BarryChief Commercial Officer$4,905,744
Jeff BurrisChief Legal Officer$3,521,215
Richard SimkinFormer Chief Commercial Officer$4,017,316

What changed and why

  • $18.5MJoe Ciaffoni became Chief Executive Officer on May 8, 2025, receiving total compensation of $18,501,214.
  • $1.24BTotal net revenue increased 4% year-over-year to $1.24 billion, driven by SUBLOCADE.
  • $856MSUBLOCADE net revenue grew 13% year-over-year to a record $856 million.
  • $428MAdjusted EBITDA increased 20% year-over-year to $428 million with a 35% margin.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.